Impact of Tumor Necrosis Factor Inhibition on Healthcare Costs in Patients with Rheumatoid Arthritis.

被引：0
|
作者：
Maksymowych, Walter P. [1 ]
Nguen Xuan Thanh [2 ]
Homik, Joanne [1 ]
Barnabe, Cheryl C. M. [1 ]
Martin, Liam [1 ]
Barr, Susan G. [1 ]
Ohinmaa, Arto [1 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Inst Hlth Econ, Edmonton, AB, Canada
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
448
引用
收藏
页码：S171 / S171
页数：1
相关论文
共 50 条
  • [41] Predictors and Modeling of Costs in Rheumatoid Arthritis.
    Eriksson, Jonas
    Frisell, Thomas
    Askling, Johan
    Neovius, Martin
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S425 - S425
  • [42] Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
    Mubashir, E
    Ahmed, MM
    Wolf, RE
    Hayat, S
    Hall, VC
    Shi, R
    Berney, SM
    JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S284 - S284
  • [43] Polymorphism in the tumor necrosis factor receptor II gene is associated with soluble receptor levels in rheumatoid arthritis.
    Glossop, JR
    Dawes, PT
    Hassell, AB
    Mattey, DL
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S357 - S357
  • [44] Cytokine blockade as a new strategy to treat rheumatoid arthritis -: Inhibition of tumor necrosis factor
    Fox, DA
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) : 437 - 444
  • [45] Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis
    Phillips, Christopher
    Zeringue, Angelique L.
    McDonald, Jay R.
    Eisen, Seth A.
    Ranganathan, Prabha
    PLOS ONE, 2015, 10 (11):
  • [46] Effects of anti-tumor necrosis factor (TNF) therapy and methotrexate on bone density in rheumatoid arthritis.
    Coulson, Kathryn
    Pepmueller, Peri
    Hinkle, Kim
    Kremer, Joel
    Reed, George
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S79 - S80
  • [47] Polymorphism at position-308 of the promoter of the tumor necrosis factor α gene and infliximab therapy in rheumatoid arthritis.
    Fonseca, JE
    Carvalho, T
    Cruz, M
    Nero, P
    Sobral, M
    Mourao, AF
    Cavaleiro, J
    Carmo-Fonseca, M
    Branco, J
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S394 - S394
  • [48] Inhibition of calpastatin function by autoantibodies in patients with rheumatoid arthritis.
    Matsumoto, M
    Takada, R
    Yoshida, M
    Hoshiyama, K
    Nojima, T
    Matsumura, M
    Ohosone, Y
    Mimori, T
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1476 - 1476
  • [49] Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.
    McInnes I.B.
    Gracie J.A.
    Current Rheumatology Reports, 2004, 6 (5) : 336 - 342
  • [50] Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis.
    Harnett, J.
    Wiederkehr, D.
    Gerber, R.
    Gruben, D.
    Koenig, A.
    Bourret, J.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S503 - S503
12345